cyrilzakka/clinical-trials huggingface dataset:
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression

Migraine is a common and possible hereditary disease. Copy number variation (CNV) is a phenomenon in which parts of the genome are repeated and the number of repeats in the genome varies between individuals in the human population.The CHRNA7 gene has a major role in the neuropsychiatric phenotypes observed in patients. The 15q13.3 gain/loss variation in this gene may be associated with migraine.

Migraine is a common neurological disorder. Although they have different genetic bases according to their types, cholinergic receptors after calcium channels play an important role in the clinic and genetics of the disease. Neuronal acetylcholine receptor subunit alpha-7, also known as nAChRα7, is a protein that in humans is encoded by the CHRNA7 gene.

Eligibility Criteria:
Inclusion Criteria:

Migraine

Exclusion Criteria:

Vascular problems
Effect of Perioperative Glycemia Protocol on Glycemic Outcomes in Diabetic Patients Undergoing Abdominal Surgery

This study evaluated to the effects of a glycaemic control protocol directed by nurses during the perioperative period on glycaemic outcomes in diabetic patients undergoing major abdominal surgery. The study was conducted at the department of general surgery of a research and training hospital.The study included 47 patients who underwent elective major abdominal surgery between September 2017 and December 2018. The number of patients in the intervention and the control groups was 22 and 25, respectively. The glycemia control protocol will be used in the glycemia management of intervention group,routine glycemia management will be used in the control group.

The prevalence of diabetes among the surgical patient population is 10-15%, and surgical operations are administered to diabetic patients more frequently compared to non-diabetic patients. Diabetes or hyperglycaemia in surgical patients increases mortality and morbidity rates during the perioperative period by 50% compared to non-diabetic patients. Maintaining patient blood glucose (BG) levels of within the target range during the surgical period is crucial to prevent postoperative complications. The target BG level has been modified in line with recent scientific findings; institutions (such as the American Diabetes Association), have prepared new guidelines for the management of glycaemia in critically ill and surgical patients. Insulin infusion is the most effective method to control glycaemia in patients with critical disease or in patients about to undergo major surgery. Therefore, current guidelines recommend the use of reliable and practical glycaemia control protocols during insulin infusion. These protocols should be learnt by all members of the team that provide healthcare. Existing studies suggest that glycaemic management protocols are effective methods to achieve the target BG range and decrease the prevalence of hyperglycaemia and hypoglycaemia in critically ill and major surgery patients in a reliable and effective way.

Eligibility Criteria:
Inclusion Criteria;

* Patients were diagnosed with type 2 diabetes
* Patients planned to undergo elective major abdominal surgery

Exclusion Criteria;

* Patients who had diabetes other than type 2 diabetes
* Patient who had a preoperative glycated haemoglobin A1C (HbA1C) value of 8.5% or greater
* Patient planned to undergo surgery related to the pancreas
The Endovascular Management of Visceral Artery Aneurysms

To describe the safety, possible complications and technical success of different technical methods and different embolic materials in the endovascular management of visceral artery aneurysms.

Abdominal visceral artery aneurysms (VAAs) are defined as aneurysms which involve branches of the celiac, superior mesenteric, inferior mesenteric or renal arteries. Owing to the improvements in imaging technology and the use of cross-sectional imaging modalities (ultrasound, computed tomography \[CT\], and magnetic resonance imaging), there is increase in the frequency of VAAs diagnosis. Although classically treated by open surgery, modern treatment strategies generally place interventional radiology techniques at the top of the treatment algorithm. Therefore, vascular interventional radiologists must become familiar with the indications for the treatment of VAA, become experienced in the different techniques, and know when to recommend treatment of VAA by interventional radiology techniques or to advocate open surgical repair.

VAAs are subdivided into true and false aneurysms. A true aneurysm involves all three layers of the arterial wall. Classically, a true aneurysm is defined as a localized dilatation of the artery by more than 1.5 times the expected arterial diameter. True aneurysms occur as a result of underlying arterial pathology such as atherosclerosis, fibromuscular dysplasia, and arteritis. The prevalence of true VAAs is 0.1-2%, and most true VAAs are asymptomatic. A minority may cause abdominal pain, which may be a harbinger of imminent rupture. VAAs are almost never large enough to be palpable by examination. False aneurysms, or pseudoaneurysms, are effectively contained ruptures of the artery that are lined by adventitia or by the perivascular tissues. False aneurysms may occur as a result of inflammation, infection, or trauma.

Eligibility Criteria:
Inclusion Criteria:

* Aneurysm due to inflammation or pancreatitis \[e.g., splenic, gastroduodenal (GDA), superiomesenteric artery (SMA), hepatic, or even renal aneurysms\].
* Aneurysm due to trauma.
* Aneurysms occurring after surgery
* Aneurysm due to penetrating peptic ulcers.

Exclusion Criteria:

* In most cases with multiple, diffuse, small aneurysms related to portal hypertension should be left untreated and followed by repeat computed tomography (CT) or magnetic resonance imaging (MRI) examinations. Once the portal hypertension and underlying cirrhotic disease is treated (e.g., via liver transplantation), the aneurysm may spontaneously decrease and completely disappear over time.
* Patient refusal.
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).


Eligibility Criteria:
Inclusion Criteria: Subjects with a PFO and cryptogenic stroke:

* PFO defined as visualization of microbubbles (during Trans Esophageal Echo (TEE)) in the left atrium within three cardiac cycles of right atrial opacification at rest and/or with Valsalva.
* Cryptogenic stroke defined as a stroke of unknown cause.
* Stroke defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:
* Symptoms persisting ≥24 hours OR
* Symptoms persisting \<24 hours with Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) findings of a new, neuroanatomically relevant, cerebral infarct.

Exclusion Criteria:

* Age \< 18 years
* Myocardial Infarction (MI) or unstable angina within 6 months.
* Severe mitral valve stenosis, severe aortic valve stenosis, or severe regurgitation.
* Left Ventricle Ejection Fraction (LVEF) \<35%.
* Uncontrolled hypertension or diabetes mellitus despite medications.
* Subjects contraindicated for aspirin or clopidogrel.
* Presence of other comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results.
* Qualifying stroke with Modified Rankin score \>3.
* Anatomy in which the device would interfere with intracardiac or vascular structures.
* Life expectancy \< 2 years.
* Participation in another clinical study that can interfere with the results of this study
* Exclusion for patients with known causes of ischemic stroke:
* Atrial fibrillation/atrial flutter (chronic or intermittent).
* Left Ventricle (LV) aneurysm, intracardiac thrombus, or tumor.
* Mitral or aortic valve vegetation or prosthesis.
* Aortic arch plaques protruding \>4 mm into the lumen.
* Atherosclerosis or arteriopathy of intra- or extracranial vessels with \>50% diameter stenosis in the artery supplying the infarcted territory.
* Another cause of right-to-left shunting (e.g., an Atrial Septal Defect (ASD) or a fenestrated atrial septum).
* Presence of an arterial hypercoagulable state.
* Lacunar infarct probably due to intrinsic small vessel as the qualifying event, defined as an ischemic stroke in the distribution of a single, small deep penetrating vessel in a patient with any of the following:
* A history of hypertension (except in the first week post stroke).
* A history of diabetes mellitus.
* Age ≥50 years.
* MRI or CT with leukoaraiosis greater than symmetric, well-defined periventricular caps, or bands (European Task Force on Age-Related White Matter Changes rating scale score \>0).
* Arterial dissection as the qualifying event.
Influence of Inguinal Hernia Repair on Sperm Autoimmunity

Influence of inguinal hernia repair on sperm autoimmunity using MAR test

All infertile male patients, visited between February 2000 and September 2020 and which were tested with MAR (Mixed Autoglobulin Reaction) test, were included in this retrospective study. Sperm quality (number of spermatozoa, motility, vitality and normal forms) were also studied in this patients. The aim of the study is to evaluate if there is a higher incidence of positive MAR test among patients undergoing inguinal hernioplasty compared to the general population

Eligibility Criteria:
Inclusion Criteria:

* Patients undergone to correction of inguinal hernia

Exclusion Criteria:

* No specific exclusion criteria were set.
Hypotension Prediction Index (HPI) SMART-BP Trial

A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.


Eligibility Criteria:
Inclusion Criteria:

1. Signed informed consent
2. Age \>18 years
3. ASA Physical Status \> 2
4. Noncardiac surgery with expected surgery duration \> 2 hours (example include: orthopedic, spine, urology, and general surgery)
5. Planned blood pressure monitoring with an arterial line catheter;
6. General anesthesia;

Exclusion Criteria:

1. Participating in another interventional Trial;
2. Contraindication to arterial blood pressure monitoring;
3. Subjects with a physical site area too limited for proper Sensor placement
4. Serum creatine \> 175 μmol/L (\>2.0 mg/dL) or CKD stage \> 3A
5. Scheduled for intracranial surgery with permissive hypotension;
6. Patient who is confirmed to be pregnant and/or nursing mothers;
7. Patients with an intra-aortic balloon pump (IABP) or ventricular assist device(s);
8. Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension;
9. Emergency surgery;
10. Require beach-chair positioning;
11. Scheduled for cardiac surgeries
12. Have previously participated in the SMART-BP trial.
Lab Study of MQX-503 in Treatment of Raynaud's

The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to cold temperatures.

Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a cold chamber, and then blood flow and skin temperature are monitored for the next two hours.

Each patient will receive multiple doses on different days so that each can serve as his/her own control in interpreting the response.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of Raynaud's phenomenon
* outpoatients
* agree to apply gel as per protocol
* willing to discontinue current vasodilator therapy
* agree to stop other investigational medication for Raynaud's
* negative pregnancy test is fertile females
* able to give written informed consent and comply with study requirements

Exclusion Criteria:

* current use of ay nitrate medication or medications that interact with nitroglycerin
* patients with a known allergy to nitroglycerin or topical gel ingredients
* patients with a history of migraine headaches
* patients with unstable medical problems
* patients with cognitive or language difficulties
* patients with screening lab values more than 20% outside of normal
* patients with open lesions at site of application
* women of child-bearing potential who are unwilling to comply with contraceptive requirements.
Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START

The purpose of the START project is to evaluate the acceptability, the safety and the cost-effectiveness of a population based program of active surveillance for patients newly diagnosed with a localized, low risk, prostate cancer.

Comparative effectiveness research project. All newly diagnosed prostate cancer patients fulfilling the low risk definition, resident in Piedmont or in Valle D'Aosta regions, will be invited to participate. All enrolled patients will receive full and clear information about their prognosis together with a balanced synthesis of the benefits and risks of the available treatments (active surveillance or radical treatments).

Specific objectives are:

* To estimate, at a population level, the proportion of newly diagnosed prostate cancer at low risk, eligible for active surveillance, the proportion of those accepting to be enrolled in a cohort of active surveillance and the risk of abandoning the program during follow-up.
* To compare the patients' and physicians' characteristics of those accepting to be managed within the active surveillance program with those preferring a radical treatment (either surgery or radiotherapy).
* To compare, at a population level, the clinical outcomes, quality of life and costs associated to different treatment choices.

Eligibility Criteria:
IInclusion Criteria:

1. Newly diagnosed low risk prostate cancer patients, defined according to the presence of all the following criteria:

   * diagnosis of adenocarcinoma of the prostate
   * prostate cancer clinical stage T1c o T2a
   * PSA \<=10ng/ml at diagnosis
   * adequate biopsy sampling according to prostate volume
   * maximum of two positive cores for random sampling and of maximum two lesions for target biopsies (even if the number of positive samples if \>2)
   * Gleason grade 3+3 ( in patients age\>70 Gleason 3+4)
2. Residence in Piemonte or Valle D'Aosta regions;
3. Patients suitable for radical treatment (surgery or radiotherapy);
4. Age at diagnosis \<= 75 years or \>75 years if fragility assessment (measured with the G8 score)\> = 14;
5. Patients suitability for expressing a valid consent to participate in the study.

Exclusion Criteria:

1. Patients previously treated for prostate cancer.
2. Patients not willing to undergo radical treatments (surgery or radiotherapy).
Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis

Amyloidosis is involved in many rare diseases in relation to the diversity of amyloid proteins involved in the formation of abnormal tissue deposits. There are approximately 30 proteins involved in amylose's constitution. The therapeutic management varies depending on the type of amyloidosis observed.

The application of conventional techniques immunolabeling of amylose does not allow the comprehensive characterization of amylose forms, due to failures of the technic, the false positivity of some results, or lack of frozen tissue available for typing light chain (lambda, kappa).

In this study, the main objective is the comparison of two capacity of amylose characterisation: immunohistochemistry and proteomics analysis.

The purpose of this study is to validate the superiority of proteomic analysis by demonstrating the improvement of the precision, the reduction of technical failure, as well as the correction of erroneous diagnosis, authorizing a more adapted therapeutic management.


Eligibility Criteria:
Inclusion Criteria:

* Upper age to 18 years
* Amylose diagnosis establish by tissue sample, after "Rouge Congo" coloration
* All patient with amylose identified by the two laboratory of anatomopathology
* Sample necessary for realized proteomic analysis
* No opposition at the participation of the study
* Patient sign an informed consent for biology collection

Exclusion Criteria:

* Tissue sample inadequate for apply immunohistochemistry or proteomic identification
* Patient trust, guardianship, under legal protection measure, deprived of freedom
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).


Eligibility Criteria:
Inclusion Criteria:

1. common warts on non-genital, non-facial skin
2. otherwise healthy
3. between 18-65 and able to give informed consent
4. capable of tolerating treatment

Exclusion Criteria:

1. Ill-health
2. Poor tolerance or sensitivity to treatments in study
3. \<18 years old; \>65 years old
4. verruca plana or condyloma acuminata
5. immunosuppression or immune dysfunction
6. significant peripheral vascular disease
7. significant sensitivity to cold
8. epidermodysplasia verruciformis
9. mosaiform warts or periungual warts
The Effect of Quercetin in Sarcoidosis

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.

Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis
* no smoking
* no treatment

Exclusion Criteria:

* clinical diagnosis (and treatment) of other diseases
* symptoms of sarcoidosis in other organs besides the lung
* use of food supplements or vitamins
Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions

The purpose of this prospective clinical trial will be to evaluate the efficacy of an FDA approved and marketed universal dental adhesive formulation in adult noncarious cervical lesions using self-etch and selective etch approaches.

The hypothesis is that using a selective enamel etch with this universal adhesive will enhance the restoration margin performance.

The purpose of this prospective clinical trial will be to evaluate the efficacy of a newly formulated universal dental adhesive formulation in adult noncarious cervical lesions using self-etch and selective etch approaches.

Thirty-three patients with at least two non-carious cervical lesions will receive one restoration utilizing the self-etch universal adhesive with no separate enamel etching and another restoration utilizing the universal adhesive and a a selective etch protocol in which in which enamel is etched with 37% phosphoric acid.

After a screening/baseline visit at which the restorative procedures listed above will conducted, the patient will be seen at recall visits after approximately 6, 12 and 24 months to observe sensitivity, retention, marginal discoloration and marginal adaptation.

Eligibility Criteria:
Inclusion Criteria:

* 1.1. Inclusion criteria

  1. Willing to provide written consent and authorization for participation.
  2. Be between 20 and 75 years of age at the time of recruitment
  3. Have at least two non-carious cervical lesions present in canine or premolar teeth;
  4. Anticipates availability for recalls (roughly 6 month, 12 month, and 24 month) through the two-year study period
  5. The lesions selected will be at least 1 mm in depth (measured with a perio probe) and contain both enamel and dentin margins.

     Exclusion Criteria:

1.2. Exclusion criteria

1. Severe medical complications (organ transplants, cancer, immunocompromised, long term antibiotic or steroid therapy);
2. Active caries on study teeth;
3. Bleeding on probing of study teeth;
4. Generalized severe periodontitis;
5. Patient reported symptoms (burning mouth, loss or diminished taste, saliva amount too little, needs liquids to eat dry foods) or clinical signs (erythematous tongue, chelitis, lack of pooled saliva) associated with dry mouth;
6. Patients determined to be at a high risk of caries as determined by a Caries Risk Assessment
Retrospective Analysis on Large Incisional Hernia in High Risk Patients

Large incisional hernia (LIH) is a challenging condition where the abdominal wall is hopelessly compromised. Nowadays the best treatment option in this particularly frail subset of patients is a major issue. The Auhtors proposed the clinical experience with an innovative approach with the composite Free Lateral Polypropylene prosthesis (FLaPp®) mesh fashioned as "neoperitoneum" analyzing its feasibility and short/medium term results.


Eligibility Criteria:
Inclusion Criteria:

* symptomatic patients with midline Large incisional hernia

Exclusion Criteria:

* lateral incisional hernias
* collagen diseases
* patients who recently have undergone chemotherapy and/or radiation therapy
* patients with acquired immunodeficiency